Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | PAICS | P22234 | 1/20 | 0.35 |
| ▸ | GAK | O14976 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029732 | 0.89 | LMNA (0.40) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6029381 | 0.88 | HPGD (0.37) | CHEK1STK17BPAICSGAKALOX15 | |
| SCHEMBL6028227 | 0.87 | LMNA (0.41) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6029268 | 0.85 | MAPT (0.43) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6028518 | 0.85 | CHEK1 (0.39) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6029438 | 0.85 | CHEK1 (0.39) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6029378 | 0.85 | LMNA (0.40) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6029156 | 0.85 | LMNA (0.41) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6169643 | 0.83 | LMNA (0.46) | POLBATMLMNARAB9ATSHR | |
| SCHEMBL6028843 | 0.83 | LMNA (0.38) | POLBATMLMNARAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984643-B2 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-01-10 | — | — | US | claimed |
| EP-1521582-A1 | 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-13 | — | — | EP | claimed |
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-01-22 | — | — | US | claimed |
| WO-2004004731-A1 | 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | claimed |
| US-6984643-B2 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1521582-A1 | 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-04-13 | — | — | EP | disclosed |
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | ROCHE PALO ALTO LLC | 2004-01-22 | — | — | US | disclosed |
| WO-2004004731-A1 | 2, 5-SUBSTITUTED PYRIMIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS IX | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014775-A1 | 2,5-substituted pyrimidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCRL2 | POLB 2585/4885ATM 1991/4885LMNA 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.